▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #10 by analyst upside · 2026-11-14
KPTIQ
Karyopharm Therapeutics Inc.
Unknown · Market Cap N/A · P/E 0x
ANALYST PRICE TARGET
+28771.4%
implied upside to consensus target
Current Price $0.03
Consensus Target $7.33
Bull Target $11.0
Bear Target $3.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
1
Sell
0
52-Week Low $0.01
52-Week High $10.99
YTD Return -77.7%
FUNDAMENTALS
Market Cap N/A
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) N/A
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $147M
Profit Margin -153.3%
52-WEEK RANGE
52-Week Low $0.01
52-Week High $10.99
Current Price $0.03
Bear Target $3.0
Bull Target $11.0
● Now $0.03 ● Target $7.33
TRADING DATA
Avg Volume 8.6M
YTD Return -77.7%
Analyst Count 3
Consensus Buy
Upside to Target +28771.4%
Last Updated 2026-11-14

ANALYST SUMMARY

Karyopharm Therapeutics Inc. (KPTIQ) is currently trading at $0.03 with a Wall Street consensus price target of $7.33, implying potential upside of 28771.4% over the next 12 months. 3 analysts currently cover KPTIQ, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $3.0.

KPTIQ operates in the Unknown sector with a market capitalisation of N/A. The stock is down 77.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.01 – $10.99.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →